Arcellx, Inc.
https://arcellx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arcellx, Inc.
Novartis Hopes To Breathe New Life Into CAR-T Business With ASCO Myeloma Data
Gilead’s Kite has taken a lead in multiple myeloma cell therapy while Novartis’s first-to-market Kymriah has slumped in sales, but the Swiss drug maker’s new data may support its effort to win on manufacturing time.
Gracell Revs FasTCar To Catch Big Pharma Rivals In Myeloma
The Chinese company’s share price has trebled in the last month thanks to impressive data at ASCO and EHA, but Gracell will need to burn rubber to close in on the frontrunners.
Gilead’s Kite Hopes To Reinforce Commercial CAR-T Lead With Yescarta Data
The company presented results from the ZUMA-7 trial at ASCO for the CAR-T therapy in the curative setting of large B-cell lymphoma.
Gilead Reports 61 Clinical Programs Under Way, With Over 20 In Phase III
Excluding sales declines due to Veklury, Gilead said its year-over-year sales grew 15% in the first quarter, with HIV drug Biktarvy serving as the biggest driver.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice